Conotoxin venom peptide therapeutics.
Venom peptides offer enormous opportunity for the discovery of peptide drug leads. This review focusses on the potential of cone snails that have developed arrays of small peptides as part of highly evolved venoms used for prey capture and defence. Many of these peptides selectively modulate ion channels and transporters, making them a valuable source of new ligands for studying the role these targets play in normal and disease physiology. A number of these conopeptides reduce pain in animals models and several are now in preclinical and clinical development for the treatment of severe pain often associated with diseases such as cancer.
Lewis
Richard J
RJ
Xenome Ltd, Indooroopilly 4068 and Institute for Molecular Biosciences, The University of Queensland, 4072, Brisbane, Australia. r.lewis@imb.uq.edu.au
D000595:Amino Acid Sequence; D000596:Amino Acids / Q000737:chemistry; D000818:Animals; D002121:Calcium Channel Blockers / Q000737:chemistry; D020916:Conotoxins / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000628:therapy; D009638:Norepinephrine / Q000378:metabolism; D010455:Peptides / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000737:chemistry; D026941:Sodium Channel Blockers / Q000737:chemistry; D014688:Venoms / Q000627:therapeutic use*
D000596:Amino Acids; D002121:Calcium Channel Blockers; D020916:Conotoxins; D010455:Peptides; D011978:Receptors, Nicotinic; D026941:Sodium Channel Blockers; D014688:Venoms; D009638:Norepinephrine